

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Biologics Evaluation and Research (CBER)
171st Meeting of the Vaccines and Related Biological Products
Advisory Committee
April 6, 2022
DRAFT AGENDA

Topic: The committee will meet in open session to discuss considerations for COVID-19 vaccine booster doses and the process for COVID-19 vaccine strain selection to address current and emerging variants

Time	Presentation/Presenter
8:30 a.m.	<p><u>Opening Remarks: Call to Order and Welcome (10 min)</u></p> <p>Arnold Monto, M.D. Acting Chair, VRBPAC Emeritus Professor of Public Health and Epidemiology, University of Michigan</p> <p><u>Administrative Announcements, Roll Call, Introduction of Committee, Conflict of Interest Statement (20 min)</u></p> <p>Prabhakara Atreya, Ph.D. Acting Designated Federal Officer, VRBPAC Director, Division Scientific Advisors and Consultants, CBER, FDA</p>
9:00 a.m.	<p><u>FDA Introduction (15 min)</u></p> <p>Welcome (5 min)</p> <ul style="list-style-type: none"> • Peter Marks, M.D. Ph.D. Center Director, CBER, FDA <p>Introduction to the Topic: COVID-19 vaccine booster vaccination (10 min)</p> <ul style="list-style-type: none"> • Doran Fink, M.D., Ph.D. Deputy Director- Clinical Division of Vaccines and Related Product Applications (DVRPA) Office of Vaccines Research and Review (OVRP), CBER, FDA
9:15 a.m.	<p><u>Update on the Epidemiology of COVID-19 Variants (35 min)</u></p> <ul style="list-style-type: none"> • CDR Heather Scobie, PhD, M.PH. (30 min) Deputy Team Lead, Surveillance and Analytics Epidemiology Task Force COVID-19 Emergency Response Centers for Disease Control and Prevention (CDC) • Q/A – 5 min
9:50 a.m.	<p><u>COVID-19 Vaccine Effectiveness in Children and Adults (25 min)</u></p> <ul style="list-style-type: none"> • LCDR Ruth Link-Gelles, PhD, M.PH. (20 min) Program Lead, COVID-19 Vaccine Effectiveness Epidemiology Task Force COVID-19 Emergency Response

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Biologics Evaluation and Research (CBER)
171st Meeting of the Vaccines and Related Biological Products
Advisory Committee
April 6, 2022
DRAFT AGENDA

	Centers for Disease Control and Prevention (CDC) <ul style="list-style-type: none"> • Q/A – 5 min
10:20 a.m.	Israeli Experience with Fourth Booster Doses in Older Adults (20 min) <ul style="list-style-type: none"> • Sharon Alroy-Preis, M.D. M.PH.M.B.A – (10 min) Director, Public Health Services Ministry of Health, Jerusalem, Israel • Ron Milo. Ph.D. - (5 Min) Professor, Dept. of Plant and Environmental Sciences, Dean of Education, Weissman Institute, Rehovot, Israel <p>Q/A – 5 min</p>
10:40 a.m.	Break (10 min)
10:50 a.m.	Predicting Future SARS-CoV-2 Variants (30 min) <ul style="list-style-type: none"> • John Beigel, M.D. (10 min) Associate Director for Clinical Research Division of Microbiology and Infectious Diseases Office of the Director, NIAID, NIH • Trevor Bedford, Ph.D. (10 Min) Professor, Fred Hutchinson Cancer Research Center Investigator, Howard Hughes Medical Inst. Seattle, WA • Q &A – 10 Min
11:20 a.m.	Modeling of Future U.S. COVID-19 Outbreaks (30 min) <ul style="list-style-type: none"> • Christopher Murray, M.D. D.Phil. (15 Min) Professor and Chair Department of Health Metrics Sciences Director, Institute for Health Metrics and Evaluation (IHME) • Ali H. Mokdad, Ph.D. (5 min) Professor, Health Metrics Sciences Chief Strategy Officer, Population Health Institute for Health Metrics and Evaluation (IHME) School of Medicine, Washington University • Q &A – 10 Min

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Biologics Evaluation and Research (CBER)
171st Meeting of the Vaccines and Related Biological Products
Advisory Committee
April 6, 2022
DRAFT AGENDA

11:50 a.m.	<p>WHO Perspective on Variants for COVID-19 Vaccine Composition (20 min)</p> <ul style="list-style-type: none"> • Kanta Subbarao, M.D. M.PH. (15 min) Director, WHO Collaborating Center for Reference and Research on Influenza, Peter Doherty Institute for Infection and Immunity Melbourne, Australia • Q &A – 5 min
12:10 p.m.	<p>Perspective on Variant Vaccine Development and Production (20 min)</p> <ul style="list-style-type: none"> • Robert Johnson, Ph.D. (15 min) Deputy Assistant Secretary Director, Medical Countermeasure Programs Biomedical Advanced Research and Development Authority (BARDA) • Q &A – 5 min
12:30 p.m.	<p>Proposed Framework for Addressing Future COVID-19 Outbreaks (30 min)</p> <ul style="list-style-type: none"> • Jerry Weir, Ph.D. (20 min) Director, Division of Viral Products Office of Vaccines Research and Review (OVRR), CBER, FDA • Q/A – 10 min
1:00 p.m.	<u>Lunch (30 min)</u>
1:30 p.m.	<u>Open Public Hearing (60 min)</u>
2:30 p.m.	<u>Committee Discussion of Questions (150 min)</u>
5:00 p.m.	<u>Meeting Adjourned</u>